Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic

Gianluca Costamagna1 · Elena Abati1 · Nereo Bresolin1,2 · Giacomo Pietro Comi1,3 · Stefania Corti1,2

Abstract
The novel Coronavirus disease-19 (COVID-19) pandemic has posed several challenges for neuromuscular disorder (NMD) patients. The risk of a severe course of SARS-CoV-2 infection is increased in all but the mildest forms of NMDs. High-risk conditions include reduced airway clearance due to oropharyngeal weakness and risk of worsening with fever, fasting or infection. Isolation requirements may have an impact on treatment regimens administered in hospital settings, such as nusinersen, glucosidase alfa, intravenous immunoglobulin, and rituximab infusions. In addition, specific drugs for SARS-CoV2 infection under investigation impair neuromuscular function significantly; chloroquine and azithromycin are not recommended in myasthenia gravis without available ventilatory support and prolonged prone positioning may influence options for treatment. Other therapeutics may affect specific NMDs (metabolic, mitochondrial, myotonic diseases) and experimental approaches for Coronavirus disease 2019 may be offered “compassionately” only after consulting the patient’s NMD specialist. In parallel, the reorganization of hospital and outpatient services may change the management of non-infected NMD patients and their caregivers, favouring at-distance approaches. However, the literature on the validation of telehealth in this subgroup of patients is scant. Thus, as the first wave of the pandemic is progressing, clinicians and researchers should address these crucial open issues to ensure adequate caring for NMD patients. This manuscript summarizes available evidence so far and provides guidance for both general neurologists and NMD specialists dealing with NMD patients in the time of COVID-19.

Keywords Neuromuscular disorders · COVID-19 · Telemedicine · Vaccine · Pandemic · Disease-modifying therapies · Neuromuscular disorder centres · Ventilatory support

Introduction
Since the end of December 2019, the severe acute respiratory syndrome virus 2 (SARS-CoV-2) pandemic has claimed the lives of more than 400,000 individuals worldwide (https://coronavirus.jhu.edu/map.html). Symptomatic SARS-CoV-2 infection causes a wide spectrum of symptoms (referred to as “Coronavirus Disease 2019", COVID-19), such as fever, dry cough, and fatigue in milder cases and systemic manifestations in severe disease courses (Fig. 1). In parallel, SARS-CoV-2 infection poses a greater risk for old, oncologic, and immunosuppressed patients, which also include many individuals with hereditary and acquired neuromuscular disorders (NMD) that may already present increased risks due to the underlying disease (see “Risk assessment and stratification” section). As already reported in other papers, the first phase of the SARS-CoV-2 pandemic has seen the overwhelming access of COVID-19 patients to the Emergency Departments prompting an urgent reorganization of personnel and facilities in worst-hit areas, such as Wuhan [1], New York [2, 3] and Lombardy [4, 5]; this reallocation of resources has also imposed changes in the short- and mid-term management of NMD outpatients and non-urgent cases, favouring the use of at-distance approaches.
1. Lungs. SARS-CoV-2 can enter lung epithelial cells through the ACE-2 receptor. The results may be cough, fever and hypoxia.

2. Nose. Patients may lose the sense of smell, sometimes persisting after recovery. It may be due to a damage of nerve endings or an involvement of upstream olfactory tracts.

3. Upper respiratory airways. Mild symptomatic cases often present sore throat.

4. Eyes. Viral particles have been detected in tears. Conjunctivitis is frequent in severe forms.

5. Skin. Erythematous rashes, urticaria and chickenpox like vesicles are possible manifestations.

6. Brain and peripheral nerves. Entrance gate to the CNS is still unclear; spread through nerves and hematogenous dissemination are possible mechanisms. Neurologic manifestations include stroke, encephalitis, seizure and Guillain-Barré syndrome.

7. Kidneys. Acute kidney injury occurs in severe cases. It may be due to viral-induced damage, drug toxicity, multiorgan failure syndrome or a combination of these.

8. Intestines. Oral transmission is a possible route of contagion. Patients may present diarrhea, abdominal pain, nausea and vomit, sometimes lacking respiratory symptoms.

9. Heart and blood vessels. Infection can induce blood clots, myocarditis and heart attacks.

10. Liver. Acute liver damage is frequent in hospitalized patients. Virus-induced, immune-mediated, drug-driven mechanisms or a combination of these are under study.

Fig. 1 Systemic involvement in SARS-CoV-2 infection. The figure shows the different organs and systems possibly involved in coronavirus disease-19 (COVID-19) infection and it summarizes some pathophysiological and clinical-related features. The virus can spread beyond the lungs and the respiratory tract, affecting the gastrointestinal, cardiovascular, renal, and nervous system. Eyes and skin may be involved as well. Possible routes of contagion include aerial, oral, and conjunctival transmission.

[6] As the first wave of the pandemic is progressing in many countries, we need adaptive strategies for the post-pandemic phase regarding NMD patients. In this sense, sharing the experience gained from centres directly involved in COVID-19 management may help the neurologic community facing common challenges.

Specifically, first-hand experiences regarding neuromuscular centres have been reported [6] and different general recommendations for NMD patients are available (e.g. World Muscle Society), but the literature on the management of non-infected and infected NMD patients during the pandemic is limited. In addition, some issues regarding NMD patients remain open: (1) drugs used compassionately for SARS-CoV-2 patients (e.g. azithromycin, chloroquine, and hydroxychloroquine) are contraindicated in some NMD patients (myasthenic patients) and can cause NMD-related complications (rhabdomyolysis, toxic neuropathies, and myopathies); (2) the use of anaesthetics, intubation, and
mechanical ventilation is the standard of care for severe SARS-CoV-2 cases in intensive care units (ICU), but it poses additional risks for NMD patients with bulbar involvement; (3) neuromuscular disorders centres should reorganize to offer the highest level of care while securing best standards of safety for the NMD patients.

Here, we aim to review the management of NMD patients with and without SARS-CoV-2 infection, focusing on COVID-19 therapies, COVID-19 drug-related complications, and ventilatory support, sharing the experience from our NMD centre in Lombardy, proposing our view for the role of NMD centres and NMD specialists during the post-acute pandemic phase and addressing the future challenges that neurologists dedicated to neuromuscular disorders will probably encounter.

The NMD patient without SARS-CoV-2 infection

Risk assessment and stratification

Risk assessment and stratification are crucial to identify NMD patients who are at increased risk to suffer from severe COVID-19 complications. National and international neurologic and neuromuscular networks have produced guidance to help both NMD patients and families and their physicians to prevent and manage SARS-CoV-2 infection in this category [6–9]. Overall, these documents recognize that the risk of severe complications from COVID-19 is high or moderately high in most NMD patients, apart from those with the mildest forms.

Features associated with high or very high risk include weakness of respiratory muscles with a reduction of respiratory volumes, use of invasive or non-invasive ventilation devices, oropharyngeal weakness determining inefficiency in airway clearance, the use of immunosuppressive treatments and the presence of severe comorbid conditions and/or multiorgan impairment [8] (Table 1).

Some conditions, such as mitochondrial diseases, metabolic myopathies and myasthenia gravis, might also determine a worse outcome because of the risk of deterioration or rhabdomyolysis [10] secondary to fever and infections. In addition, patients receiving steroid treatment might undergo an adrenal crisis during fever or infection if steroid dosage is not adjusted [11]. Patients with conditions that do not affect respiratory and swallowing functions and whose immunocompetence is not affected by medications are generally not considered to be high risk [8]. However, there are additional risk factors that might add to the pre-existent neurologic condition and increase the risk in the single patient (Table 2).

Therefore, risk assessment should be carried out on a case-by-case basis. It is worth pointing out that highly-dependent patients that need help from caregivers in basic activities of daily living (BADL) present an increased risk due to their impossibility to isolate [12].

Following available guidelines, and in the opinion of the authors, NMD patients who do not present a high or very high risk of severe complications should follow general rules outlined in the World Muscle Society (WMS) guidelines [8]. Conversely, high-risk patients should be advised to practice “shielding”, that means not leaving their home and avoid any face-to-face contact and social situation unless extremely necessary [9].

| Table 2 | Additional risk factors increasing the risk of developing severe COVID-19 disease |
|--------|----------------------------------------------------------------------------------|
| Kyphoscoliosis |
| Highly-active immune-mediated neuromuscular disease |
| Mild respiratory muscle weakness |
| Other medical comorbidities: |
| • Pulmonary diseases |
| • Liver diseases |
| • Neutropenia/lymphopenia |
| • Renal diseases/impairment |
| Other factors: |
| Older age |
| Pregnancy (possible) |
| Concomitant additional neurologic diseases |
| Dependence from caregivers in hygiene, mobilization and feeding |

| Table 1 | Factors conferring a high or very high risk of developing severe COVID-19 complications |
|---------|----------------------------------------------------------------------------------|
| Muscular weakness of the chest and/or diaphragm, resulting in respiratory volumes less than 60% predicted |
| Use of non-invasive or invasive ventilation devices |
| Presence of tracheostomy |
| Presence of dysphagia and oropharyngeal weakness (reduced airway clearance) |
| Primary cardiac involvement |
| Risk of deterioration with fever, fasting or infection |
| Risk of rhabdomyolysis with fever, fasting or infection |
| Concomitant diabetes, obesity, neoplastic diseases, severe cerebrovascular diseases or severe heart diseases (heart failure, ischemic heart disease) |
The role of neuromuscular centres

The SARS-CoV-2 pandemic has forced a quick reorganization of hospital facilities and outpatient services to address new patients’ needs. Local differences in response have depended mainly upon geographical localization of hospitals, patient population, distribution of sick patients, and the overall organization of the health care system [6, 13]. In our case, we may distinguish between two different phases of the response to the pandemic.

During the first days after the virus spread in our area, the need for intensive and sub intensive care beds in hospitals selected as “COVID Hubs” (appointed by the authorities), the shortage of PPE and the increased infection risk for patients imposed consistent changes in the management of our NMD patients. Elective or “non-urgent” patient visits were postponed to avoid unnecessary exposure for patients and clinical staff favouring virtual encounters. Other services, such as electrodiagnostic tests, muscle, and nerve biopsies, were suspended unless urgent cases required further evaluations (such as new diagnosis of amyotrophic lateral sclerosis, myasthenia, myositis, or immune-mediated neuropathies). Ancillary services needed reorganization of personnel and resources: pulmonary assessments were stopped due to increased risk of viral shedding from tested patients; tests for dysphagia were performed for cases at increased risks of complications or unplanned hospitalizations; speech therapy and neuropsychological evaluations, whenever possible, were conducted on virtual platforms.

In the second phase of the pandemic, when the curve of COVID-19 cases started to flatten and COVID-dedicated facilities were partially dismissed, we adopted new strategies for our NMD patients (Fig. 2). At the time of writing, the number of new daily cases in many western countries is decreasing (see COVID map link), but strategies to effectively resume subspecialty outpatients’ clinics and to reorganize hospital settings in the post-acute pandemic phase still lack. National and international recommendations, though heterogeneous, identify some higher-risk subjects that may need prolonged strict preventive measures even after the worst phases of the pandemic, such as adults older than 65, immunocompromised, and cancer patients (e.g. https://www.esmo.org/for-patients/patient-guides/cancer-care-during-the-covid-19-pandemic) (Tables 1 and 2). NMD patients at higher risks for SARS-CoV-2 complications should be included in this list (see “Risk assessment and stratification” section). Depending on the number of new cases, COVID-dedicated hospitals should be reorganized to permit the management of outpatients and the provision of ancillary services, if possible; if not, referral centres for NMD patients should implement robust telemedicine services to allow for proper online visits and patient’s caring (see “Telehealth and telerehabilitation” section).

We believe that low-risk individuals—who include most of NMD patients—could be assessed in COVID hospitals, using proper precautions regarding both facilities and PPE; patients should be cared for in separate, non-COVID buildings, they should wait in uncrowded waiting rooms, and should hygienize their hands and wear face masks and gloves at the facility entrance, similar to measures adopted in previous epidemics [14].

An initiative that may help neuromuscular centres to reorganize patient care is the use of quality-of-life surveys sent to NMD patients to follow up on their feelings and needs and consequently modulate appropriate responses, as already assessed in immunocompromised patients [15]. In parallel, nationwide surveys may help to quickly identify NMD patients who suffered from severe SARS-CoV-2 infection in other regions/states of the country and promptly manage possible complications—such as ventilation-associated pulmonary damage, critical-illness myopathies, and neuropathies and emerging COVID-related neurologic manifestations [16–18]—that were reported during the SARS-CoV-1 pandemic in 2002–2004 [19].
Telehealth and telerehabilitation

The pandemic has prompted a reorganization of rehabilitation services as well. Rehabilitation patients’ admission has been reduced in different countries to sustain increased hospital bed capacity and home-based rehabilitation services have been suspended or offered at-distance [13]. Alternatives for face-to-face visits include telemedicine that refers to the provision of health care services using technology, such as text, e-mail, telephone, and video [20, 21]. Despite different studies assessing the use of telemedicine—including telerehabilitation—for patients with chronic neurologic conditions exist [22, 23], the available literature on NMD patients is scarce.

Overall, three unblinded studies on the use of telemu

The extent to which immunosuppressive drugs can contribute to severe forms of SARS-CoV-2 infection is still unclear. Depending on the regional pandemic burden, patient compliance, and caregivers’ support, NMD specialists may want to consider a reduction of the dose of some immunosuppressive drugs or shift to less immunosuppressive alternatives for high-risk patients [6]. This decision should imply a careful

by movement against gravity, assessed with weights or resistive tools, or by functional activities, such as standing up from a sitting position with or without assistance. The nuances of deep tendon reflexes may be challenging via virtual approaches; however, a caregiver, if present, may be instructed to grossly evaluate briskly increased, reduced or asymmetric reflexes by tapping with fingers or objects [20]. A recent example of a neurologic examination at-distance comprises a suspected diagnosis of SARS-CoV-2 infection in a young patient with Charcot–Marie–Tooth polyneuropathy undergoing post-surgical telerehabilitation sessions [36]. Disease and non-disease-specific scales have been proposed for patients with NMD. Particularly, Revised ALS Functional Rating Scale (ALSFRS-R) for amyotrophic lateral sclerosis and Myasthenia Gravis Activities of Daily Life (MG-ADL) for myasthenia gravis are validated, disease-specific scales potentially useful for remote evaluations. Other proposed, non-disease-specific scales include Myo-FRS for myopathies and Nerve-FRS (N-FRS) for neuropathies, which may be practical tools for assigning a functional score [37]. Altogether, these results suggest that telemu

Disease-modifying therapies

Different expert panels [38] and international societies (e.g. Muscle Dystrophy Society) have already provided general recommendations regarding disease-modifying therapies used in NMD patients that may increase the risk of infection or a more severe disease course. As a general rule, NMD patients should continue to take their medications, unless diff

ly instructed by an NMD specialist via telephone or online. These medications include also newly FDA and/or EMA approved drugs, such as enzymatic replacement therapy (ERT) for Pompe disease, antisense oligonucleotides (ASO) for Duchenne Muscular Dystrophy (DMD) patients with deletions amenable to exon 51 skipping, splicing-modulator ASO and gene therapy for Spinal Muscular Atrophy (SMA), and messenger-RNA interfering molecules for transthyretin (TTR) amyloidotic neuropathy. The challenge with these drugs lies more within the highly specialised setting required for their administration, involving recurrent visits to hospital tertiary centres, rather than within specific contraindications of the administered compounds.

Several NMDs recognise immune-mediated pathogenesis. The extent to which immunosuppressive drugs can contribute to severe forms of SARS-CoV-2 infection is still unclear. Depending on the regional pandemic burden, patient compliance, and caregivers’ support, NMD specialists may want to consider a reduction of the dose of some immunosuppressive drugs or shift to less immunosuppressive alternatives for high-risk patients [6]. This decision should imply a careful
discussion with the patients on the overall risk, specific benefits, and potential adverse events of the new treatment. Regarding corticosteroid therapy, abrupt withdrawal may induce flares of the underlying condition, requiring higher doses of steroids and increasing the risk for hospitalization [39].

Currently, no evidence suggests that immunoglobulin therapy (intravenous or subcutaneous), plasma exchange, or Fc receptor antagonists (efgartigimod, currently tested in clinical trials for myasthenia gravis (MG)) [40] may increase the risk of infection or a severe disease course.

Immunomodulant therapies currently used in NMD patients may help against SARS-CoV-2 infection. Some severe SARS-CoV-2 cases with acute respiratory insufficiency may be associated with complex immune dysregulation and excessive activation of inflammatory pathways [41]. At the time of writing, some cytokine inhibition strategies are currently being tested for the treatment of COVID-19, such as Tocilizumab and Eculizumab, but their efficacy in COVID-19 patients is still unclear; several clinical trials (NCT04288713 for eculizumab; NCT04317092; NCT04310228 and others for tocilizumab) are currently ongoing worldwide.

An adequate provision of drugs represents another key issue for NMD patients. Frequent visits to pharmacies may expose them to unnecessary risk. However, during the pandemic, many pharmacies have expanded their services, waiving fees for home-delivery, and extending refill periods [42].

The NMD patient with SARS-CoV-2 infection

SARS-CoV-2 infection in NMD patients

Clinical syndromes associated with SARS-CoV-2 infection have been classified by the World Health Organization (WHO) as uncomplicated disease, mild pneumonia, severe pneumonia, acute respiratory distress syndrome (ARDS), sepsis, and septic shock [7]. In case of symptoms suggestive for SARS-CoV-2 infection, NMD patients should follow local health authorities’ policies, call their health care provider to receive guidance on treatments, testing, and monitoring [9], and contact their neuromuscular specialist to discuss possible drug dosages adjustments and potential treatments. The decision to temporarily withhold or reduce immunosuppressant medication should be discussed with the neuromuscular specialist, and should never be done by the patient without consultation [8, 38]. Most patients with COVID-19 have a mild disease course and should continue the current best practice standard of care [38]. Patients receiving corticosteroids might require an increase in treatment doses due to the risk of infection-triggered hyposurrenalism [38]. However, decisions regarding treatment de-escalation should be individualized according to the severity of infection, the risk for disease exacerbation, and the intensity of immunosuppression [38].

Inpatient admission should be avoided when possible, but it should not be delayed if necessary [8]. Indeed, patients with baseline reduction of breathing capacity and pulmonary volumes are especially at risk of rapid worsening of the disease. We suggest preparing an Emergency card stating specific respiratory and treatment needs of the single patient, including settings for ventilatory devices [9]. Furthermore, we suggest that myasthenic patients have ready with them a list of medications to avoid and that all patients with muscular involvement ensure they have a card stating pharmacological requirements for general anaesthesia [9].

Patients, caregivers, and their physicians and neurologists should bear in mind that, in an emergency setting, such as during the SARS-CoV-2 pandemic, hospitals may have to apply a ceiling of care based on age and pre-existing conditions [43–45]. In a setting of scarce resources (e.g. insufficient ICU capacity, unavailability of CPAP devices, etc.), triaging on ICU admission may have been instituted [43–45]. However, the differences between outcomes and treatability of different neuromuscular conditions might not be known to all emergency and intensive care specialists, thus neurological consult should be sought and promptly provided whenever doubts arise regarding the proper treatment of NMD patients. Even in the case of critically ill NMD patients, the role of the NMD specialist remains crucial. To guarantee a fair provision of intensive care to NMD patients, the NMD specialist should establish a close collaboration with respiratory and intensive care specialists. As there is great variability among NMD patients in terms of prognosis, treatability, and disease stage, these patients should not be denied life-saving treatments only based on their disability and without consultation with a neurologist or NMD specialist [45]. To facilitate decisions in case neurological consult is not promptly available, the French Rare Health Care for Neuromuscular Disorders Network developed a list of neuromuscular diseases usually carrying a good prognosis, that could be eligible for admission in ICU, and, for other conditions not on the list, criteria suggesting a favorable outcome in case of ICU admission [45].

Conditions with a good prognosis for recovery include autoimmune and congenital myasthenia, metabolic myopathies, inflammatory myopathies without severe systemic damage (in particular, pulmonary fibrosis), muscle channelopathies, and most neuropathies, hereditary or acquired [45]. The positive criteria for a good prognosis for intensive care in these patients are no major cardiac or respiratory damage and no major disability.

For other patients, the criteria in favor of resuscitation/ICU admission are [45]:
Neuromuscular pathologies with slight progression
Respiratory functions being minimally impaired and stabilized
Mild and stabilized heart disease
Absence of severe thoracic deformities/severe contractures preventing ventral decubitus
Absence of multisystemic impairment and comorbidities
Preservation of autonomy for everyday life acts and/or social environment to supplement daily life tasks (e.g., presence of a family and caregivers)

Similarly, patients with end-stage or incurable diseases should be encouraged to discuss with their loved ones their wishes regarding resuscitation and intubation, and, if necessary, to write them down beforehand.

Limited literature exists on the clinical course and recovery of NMD patients with SARS-CoV-2 infection. A small case series of 5 immunosuppressed MG patients showed high variability of disease severity and outcome [46]. Three of them developed severe respiratory insufficiency following the infection and required intubation or high-flow oxygen, whereas two had a milder disease course. Four of them had a favourable outcome. Indications of therapy discontinuation in immunosuppressed MG patients during the infection are uncertain [38]. Although this patient population lacks a long-term follow-up, in which an exacerbation may present, mycophenolate was discontinued in two patients without recovery [47]. In some MG patients, SARS-CoV-2 pulmonary infection may directly induce an MG crisis [46, 47].

Oxygen therapy and ventilatory support

WHO recommends that all patients with SARS-CoV-2 severe acute respiratory infection (SARI) are started immediately with supplemental oxygen therapy at 5 L/min and that flow rates are titrated to reach target \( \text{SpO}_2 \geq 90\% \) [7]. However, NMD patients should be closely monitored and early invasive or non-invasive ventilatory support should be considered in NMD patients who develop interstitial pneumonia, as hypoxemia might quickly lead to pump failure due to exhaustion and weakness of respiratory muscles, even in previously compensated patients, and hypercapnia may worsen disease course.

Hypercapnia is not a classic feature of SARS-CoV-2 pneumonia, and its appearance might signal the onset of respiratory muscle weakness [7]. Furthermore, extensive interstitial pneumonia or acute respiratory distress syndrome (ARDS) usually does not respond to oxygen therapy alone, even when oxygen is delivered via a face mask with reservoir bag, as a hypoxic respiratory failure in ARDS is usually the result of intrapulmonary ventilation-perfusion mismatch or shunt and therefore requires mechanical ventilation [7]. Indeed, acute hypoxic respiratory failure requiring respiratory support was the main reason for ICU admittance in large cohorts of COVID-19 patients [48–52]. The median arterial blood oxygen (\( \text{PaO}_2 \)) to fraction of inspired oxygen (\( \text{FiO}_2 \)) ratio on ICU admission spanned from 136 to 169 [48–50], very low levels, thus requiring high levels of Positive End-Expiratory Pressure (PEEP). Thereby, the need of endotracheal intubation (ETI) and invasive mechanical ventilation in published studies on critically ill COVID-19 patients ranged from 30% (Wuhan, China) [52], 42% (Wuhan, China) [51], 47% (Wuhan, China) [50] to 71% in Washington State, US [49] and 88% in Lombardy region, Italy [48].

Conversely, ICU patients that could be managed with non-invasive ventilation were, respectively, 62% [52], 56% [51], 42% [50], 19% [49] and 11% [48]. As regards NIV, data on Middle East Respiratory Syndrome (MERS) patients suggest a high failure rate [53]. Moreover, NIV carries the risk of widespread diffusion of exhaled air and airborne viral transmission, although recent reports show that newer systems with good interface fitting might reduce this risk [54, 55]. It is recommended that patients receiving a trial of NIV remain in a monitored setting, with the possibility of rapid ETI in case of acute deterioration or lack of improvement [7].

ETI and mechanical ventilation remain the mainstay of treatment for unstable patients with ARDS and acute respiratory insufficiency. High levels of PEEP are generally required in COVID-19 patients with ARDS [48], and in case of severe ARDS, prone positioning is recommended [7]. As regards NMD patients, anaesthetic risk varies widely, as it depends mainly on baseline muscular and ventilatory function and the presence of comorbidities [56]. In some cases, the atrophy of masticatory muscles and limited mobility of the cervical spine may complicate ETI procedure [57]. In these cases, intubation should be performed following guidelines for difficult airway management [58]. Another reason for concern in this kind of patients is the potential of side effects from neuromuscular blockers and anaesthetic agents. Depolarizing muscle relaxants (succinylcholine) are contraindicated in NMDs because of the risk of fatal hyperkalemia and rhabdomyolysis [59]. Non-depolarizing muscle relaxants (e.g. rocuronium, rapacuronium, atracurium) should be used with caution and require dose reduction and careful titration in some categories of NMDs (myotonic disorders, myasthenia gravis, Lambert–Eaton myasthenic syndrome, spinal muscular atrophy, polymyositis, and immune-mediated neuropathies) that present impaired production of choline acetyltransferase and acetylcholinesterase, and reduced concentration of acetylcholine at the endplate [59]. As concerns sedation, intravenous anaesthetics are preferable to volatile agents in most neuromuscular patients [59].
| Drug                                      | Results so far                                                                 | Potential NMD-relevant side effects                                      |
|-------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Chloroquine (CQ)/Hydroxychloroquine (HCQ) | Open label studies of HCQ + azithromycin found an increased rate of viral load reduction or disappearance and clinical amelioration in most patients [60, 61] | QTc interval prolongation, favoring fatal arrhythmias, such as ventricular tachycardia and torsade de points, especially when combined with other QTc-prolonging drugs [63] |
|                                           | Randomized study of high vs. low dose of CQ failed to detect benefits (small sample size?) but higher CQ dosage not recommended because of potential cardiac toxicity [62] | CK elevation common                                                      |
|                                           |                                                                               | Long-term use associated with risk of developing toxic neuromyopathy [64] and with onset or worsening of MG [65] |
| Lopinavir/Ritonavir (LPV/RTV)             | Randomized trial found it did not improve outcome compared to SSC alone       | QTc interval prolongation, favoring fatal arrhythmias, such as ventricular tachycardia and torsade de points, especially when combined with other QTc-prolonging drugs |
|                                           |                                                                               | Risk of toxic myopathy in association with statins                       |
| Remdesivir                                | 61 patients with severe COVID-19 were treated with remdesivir on a compassionate use basis: 68% of patients showed improvement, 15% worsened [66] | Myalgias in healthy controls [67]                                         |
|                                           |                                                                               | Elevation in liver enzymes [66]                                           |
| Azithromycin                              | Open label studies of HCQ + azithromycin found increased rate of viral load reduction or disappearance and clinical amelioration in most patients [60, 61] | QTc interval prolongation                                                 |
|                                           | Decrease in CRP levels in five patients receiving two or more TCZ administrations | Risk of worsening MG                                                      |
| Tocilizumab (TCZ)                         | Clinical amelioration and drop in inflammatory markers in 4 critically ill patients treated with ECZ [68] | Elevation in liver enzymes                                               |
| Eculizumab (ECZ)                          |                                                                               | Myalgias and arthralgias                                                  |

CK, creatine kinase; CQ, chloroquine; CRP, C-reactive protein; ECZ, eculizumab; HCQ, hydroxychloroquine; LPV/RTV, lopinavir/ritonavir; MG, myasthenia gravis; SSC, standard supportive care; TCZ, tocilizumab

### Treatments for SARS-CoV-2 and NMD Diseases

Several drugs are currently undergoing clinical trials for use against COVID-19 and, in many countries, compassionate use for patients with severe disease has been approved (Table 3).

Chloroquine (CQ) and its less toxic derivative, hydroxychloroquine (HCQ), have been developed as antimalarial drugs; nowadays, they are used also for chronic rheumatic diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (AR). These drugs also show antiviral activity [69], and recent reports have drawn attention to a possible benefit of CT against SARS-CoV-2 at high doses [70–74]. One open-label study and one randomized (high vs. low dose) study were conducted, but evidence regarding its efficacy is still lacking [61, 62, 75]. Lopinavir/Ritonavir (LPV/RTV) is an antiviral drug used for the treatment of HIV. A randomized Chinese trial found no efficacy of LPV/RTV compared to standard supportive care in patients with severe COVID-19 pneumonia [76], but other studies are currently ongoing (www.clinicaltrials.gov). Remdesivir is a novel nucleotide analogue developed for the treatment of Ebola and Marburg viruses. Remdesivir was shown to have in vitro antiviral activity against SARS-CoV-2 in vitro [73] and, in a cohort of patients with severe COVID-19 treated with remdesivir, the majority showed clinical improvement [66]. However, a randomized study conducted in China failed to show statistically significant differences between treated and placebo group, although a slightly faster clinical improvement was observed in the former group [77]. Further studies are now underway to better clarify Remdesivir efficacy (www.clinicaltrials.gov). Azithromycin is a macrolide antibiotic that may be able to suppress inflammation [78] and be effective as adjunctive therapy in ARDS [79]. It is now being studied as an adjunctive treatment for patients with COVID-19, with apparently positive results, but validation in randomized trials is needed [60, 61]. Tocilizumab is a monoclonal antibody targeting interleukin-6 receptor (IL-6R), inhibiting signal transduction and, thus, counteracting the effects of pro-inflammatory interleukin-6 (IL-6), that was shown to be involved in inflammatory storms in severe COVID-19 [80]. For this reason, the use of Tocilizumab was advocated in severe COVID-19 patients, and many clinical trials are now ongoing (www.clinicaltrials.gov), although published reports so far are scarce and anecdotal [81, 82]. Eculizumab is another monoclonal antibody directed against complement component 5 (C5), a member of the complement cascade, inhibiting its cleavage into C5a and C5b, both with proinflammatory and
prothrombotic properties. The use of Eculizumab for treatment of severe COVID-19 is currently being investigated in a clinical trial (NCT04288713), and preliminary results on 4 critically ill patients were favourable [68]. Notably, Eculizumab has recently been studied as a therapeutic agent in generalized MG [83, 84].

The most dangerous complication that may arise during short-term treatment with such agents is QTc prolongation and arrhythmias [62, 63]. In addition to CQ/HCQ, many drugs that are now used against COVID, such as azithromycin and lopinavir/ritonavir, hold potential for QTc prolongation [85], which may already be altered in NMD patients, such as individuals with myotonic dystrophy [86]. The Canadian Heart Rhythm Society has released guidelines to minimize the risk of drug-induced ventricular arrhythmias [85]. In this document, they recommend performing baseline electrocardiography (ECG) in patients with an increased risk of rhythm alterations. If QTc is moderately prolonged, optimization of medications and electrolytes may permit therapy, while in patients with markedly prolonged QTc these therapies should be avoided [85]. CQ and HCQ are also associated with CK increase and, in long-term treatments, with the development of toxic neuropathy and myopathy [64, 87]. Furthermore, reports describe drug-induced myopathies and rhabdomyolysis in patients treated concomitantly with LPV/RTV and statins [88, 89]. For this reason, we recommend a careful risk/benefit assessment before use in myopathic patients, and, in case of treatment with these agents, regular monitoring of serum CK levels. HCQ and azithromycin also have the potential to cause the onset or worsening of myasthenia gravis, and thus use in these patients should be carefully evaluated [65, 90]. We do not recommend using these drugs as prophylaxis in NMD patients, as their prophylactic efficacy has not been proven and it may lead to serious toxicity [38].

Treating the underlying NMD disease in SARS-CoV-2 patients may be challenging. One report describes the therapy of an MG exacerbation presenting with dysphagia, neck weakness, and diplopia during the infection. Anand et al. [46] administered intravenous immunoglobulin (IVIg) (2 g/kg/die) and increased dose of steroids (from 2.5 mg every other day at basal to 20 mg per day during the infection). In another report, a SARS-CoV-2 case with ETI experienced an MG crisis involving the proximal upper and lower extremities [47]. This patient was treated with prednisone (increased from 20 to 40 mg twice daily), pyridostigmine, and IVIg (0.4 g/kg for five days). Due to a worsening of the proximal weakness of upper and lower limbs, another course of IVIg (650 mg/kg for two days) was performed. In both cases, the outcome was favourable.

Overall, the literature on NMD patients with SARS-CoV-2 infection is limited in number and general considerations are difficult. Best management for MG patients with SARS-CoV-2 may represent a dilemma and the use of large registries may prove helpful to improve care for this patient population.

**Concluding remarks**

In this work, we have reviewed the existing literature regarding the management of NMD patients with and without SARS-CoV-2 infection, addressing the concerns and challenges on the recommendations on disease-modifying therapies, the use of oxygen and ventilatory support, the contraindications and complications of drugs used in COVID-19 patients, and the implementation of telehealth approaches for NMD patients. Besides, we have shared our experience from Lombardy, one of the SARS-CoV-2 worst-hit areas worldwide, our thoughts on the role of NMD specialists in the pandemic and our view on the current and future role of NMD centres, hoping to help the Neurological community in this common effort against the coronavirus.

Different reports on SARS-CoV-2 impact on neurologic patients have been published in different countries with unprecedented speed and collaboration among centres, but several questions regarding NMD patients remain unanswered. Given the possibility of subsequent waves of the pandemic, we will need a robust reorganization of neuromuscular centres, where the role of telemedicine will be prominent. We will have to stay vigilant on COVID-19 infection- and COVID-19 therapy-related NMD complications, patients with pre-existing NM diseases and new drugs that may worsen specific NMD conditions.

Finally, a strong collaboration among centres and institutions in the Neurology community will be fundamental and will provide the data to help patients with NM disorders; sharing near real-time information, using virtual communication platforms, receiving constant follow-ups from patients in the form of online surveys and updating uniform national and international guidelines may prove valuable in the mid-term period.

Now more than ever, the old saying holds: “no man is an island”.

**Availability of data and materials**

All data generated or analysed during this study are included in this published article (and its supplementary information files).
Acknowledgements We gratefully thank the Associazione Centro Dino Ferrari for its support.

Author contributions GC and EA developed the idea, did the literature search, framed the outline, and wrote the manuscript. NB, GPC, and SC supervised, gave helpful advice, and worked on different aspects of the manuscript. All authors commented on the manuscript and approved the final version.

Funding Open access funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement. This study was funded by Italian Ministry of Health Ricerca Corrente Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 2020 to GC and NB.

Compliance with ethical standards

Conflicts of interest The authors declared that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Zhang Q, Cheng S, Cheng Q (2020) Experience summary of a COVID-19 designated community hospital and its operation model. Panminerva Med. https://doi.org/10.23736/S0031-0808.20.03908-7
2. Waldman G, Mayeux R, Claassen J, Agarwal S, Willey J, Anderson E, et al. (2020) Preparing a neurology department for SARS-CoV-2 (COVID-19): early experiences at Columbia University Irving Medical Center and the New York Presbyterian Hospital in New York City. Neurology 94(20):886–891. https://doi.org/10.1212/WNL.000000000009519
3. Peters AW, Chawla KS, Turnbull ZA (2020) Transforming ORs into ICUs. N Engl J Med 382(19):e52. https://doi.org/10.1056/NEJMc2010853
4. Grasselli G, Pesenti A, Cecconi M (2020) Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 323:1545–1546
5. Filippi M (2020) Invited commentary: being a neurologist in the COVID-19 era: an experience from Northern Italy. Neurology Blogs. https://blogs.neurology.org/global/invited-commentary-being-a-neurologist-in-the-covid-19-era-an-experience-from-northern-italy/. Accessed 28 Apr 2020
6. Guidon AC, Amato AA (2020) COVID-19 and neuromuscular disorders. Neurology. https://doi.org/10.1212/WNL.000000000009566
7. World Health Organization (2020) Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. https://apps.who.int/iris-pros.lib.unimi.it:2050/iris/handle/10665/330854. Accessed 26 Apr 2020
8. World Muscle Society (2020) Covid-19 and people with neuromuscular disorders: World Muscle Society position and advice. https://www.worldmusclesociety.org/news/view/150
9. Muscular Dystrophy Canada (2020) COVID-19 and neuromuscular patients. https://neuromuscularnetwork.ca/news/covid-19-and-neuromuscular-patients-la-covid-19-et-les-patients-neuromusculaires/
10. Scalco RS, Gardiner AR, Piteathly RD, Zanotelli E, Becker J, Holton JL et al (2015) Rhabdomyolysis: a genetic perspective. Orphanet J Rare Dis. https://doi.org/10.1186/s13023-015-0264-3
11. Joseph RM, Hunter AL, Ray DW, Dixon WG (2016) Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. Semin Arthritis Rheum 46:133–141
12. Armitage R, Nellums LB (2020) The COVID-19 response must be disability inclusive. Lancet Public Health 5:e257
13. Fagiuoli S, Lorini FL, Remuzzi G (2020) Adaptations and lessons in the province of Bergamo. N Engl J Med 382:e71
14. Twu S-J, Chen T-J, Chen C-J, Olsen SJ, Lee L-T, Fisk T et al (2003) Control measures for severe acute respiratory syndrome (SARS) in Taiwan. Emerg Infect Dis 9:718–720
15. Pulvirenti F, Cinetto F, Milito C, Bonanni L, Pesce AM, Lodori G et al (2020) Health-related quality of life in common variable immunodeficiency Italian patients switched to remote assistance during the COVID-19 pandemic. J Allergy Clin Immunol. https://doi.org/10.1016/j.jaip.2020.04.003
16. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q et al (2019) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2020.1127
17. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. (2020) Guillian–Barré syndrome associated with SARS-CoV-2. N Engl J Med 382(26):2574–2576. https://doi.org/10.1056/NEJMc2009191
18. Zhao H, Shen D, Zhou H, Liu J, Chen S (2020) Guillian-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. https://doi.org/10.1016/S1474-4422(20)30109-5
19. Tsai L-K, Hsieh S-T, Chao C-C, Chen Y-C, Lin Y-H, Chang S-C et al (2004) Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol 61:1669–1673
20. Grossman SN, Han SC, Balcer LJ, Kurzweil A, Weinberg H, Galetta SL et al (2020) Rapid implementation of virtual neurology in response to the COVID-19 pandemic. Neurology. https://doi.org/10.1212/WNL.0000000000009677
21. Howard IM, Kaufman MS (2018) Telehealth applications for outpatients with neuromuscular or musculoskeletal disorders. Muscle Nerve 58:475–485
22. Hatcher-Martin JM, Adams JL, Anderson ER, Bove R, Burrus TM, Chehrenema M et al (2020) Telemedicine in neurology. Neurology 94:30
23. Davis LE, Coleman J, Harnar J, King MK (2014) Teleneurology: a feasibility and acceptability. Amyotroph Lateral Scler Frontotemporal Degener 15:473–477
24. Geronimo A, Wright C, Morris A, Walsh S, Snyder B, Simmons Z (2017) Incorporation of telehealth into a multidisciplinary ALS Clinic: feasibility and acceptability. Amyotrophic Lateral Sclerosis and Motor Neuron Disease 18:555–561
25. Pulley MT, Brittain R, Hodges W, Frazier C, Miller L, Matyjasik-Liggett M et al (2019) Multidisciplinary amyotrophic lateral sclerosis telemedicine care: the store and forward method. Muscle Nerve 59:34–39
26. Van De Rijn M, Paganoni S, Levine-Weinberg M, Campbell K, Swartz Ellrod A, Estrada J et al (2018) Experience with telemedicine in a multi-disciplinary ALS clinic. Amiotrophy Lateral Scler Frontotemporal Degener 19:143–148

27. Selkirk SM, Washington MO, McClellan F, Flynn B, Seton JM, Strozewski R (2017) Delivering tertiary centre specialty care to ALS patients via telemedicine: a retrospective cohort analysis. Amiotrophy Lateral Scler Frontotemporal Degener 18:324–332

28. Hobson EV, Baird WO, Cooper CL, Mawson S, Shaw PJ, Medermott C (2016) Using technology to improve access to specialist care in amyotropic lateral sclerosis: a systematic review. Amiotrophy Lateral Scler Frontotemporal Degener 17:313–324

29. Craig J, Chua R, Russell C, Patterson V, Wootton R (2000) The cost-effect eness of teleneurology consultations for patients admitted to hospitals without neurologists on site. 1: a retrospective comparison of the case-mix and management at two rural hospitals. J Telemed Telecare. https://doi.org/10.1258/1357633001934122

30. Portaro S, Calabrò RS, Bramanti P, Silvestri G, Torrisi M, Conti-Nibali V et al (2018) Telemedicine for Facio-Scapulo-Humeral Muscular Dystrophy: a multidisciplinary approach to improve quality of life and reduce hospitalization rate? Disabil Health J 11:306–309

31. Wilson AM, Ong MK, Saliba D, Jamal NL (2019) The veterans affairs nephropathy scale: a reliable remote polyneuropathy exam. Front Neurol. https://doi.org/10.3389/fneur.2019.01050

32. Wilson AM, Jamal NL, Cheng EM, Inkelas M, Saliba D, Hanssen A et al (2020) Telenueroscopy clinics for polyneuropathy: a pilot study. J Neurol 267:479–490

33. Khan F, Amatya B, Kesselring J, Galea M (2015) Telerhabilitation for persons with multiple sclerosis. Cochrane Database Syst Rev CD010508

34. Levy CE, Silverman E, Jia H, Geiss M, Omura D (2015) Effects of physical therapy delivery via home video telerhabilitation on functional and health-related quality of life outcomes. J Rehabil Res Dev 52:361–370

35. Bettrer JP, Thoumi A, Marquevich V, Groote WD, Battistella LR, Inamura M et al (2020) COVID-19: maintaining essential rehabilitation services across the care continuum. BMJ Global Health 5:e002670

36. Prada V, Bellone E, Schone a, Grandis M (2020) The suspected SARS-CoV-2 infection in a Charcot-Marie-Tooth patient undergoing postural rehabilitation: the value of telerhabilitation for evaluation and continuing treatment. Int J Rehabil Res. https://doi.org/10.1097/MRR.0000000000000418 [Publish Ahead of Print]

37. Garibaldi M, Siciliano G, Antonini G (2020) Telemedicine for neuromuscular disorders during the COVID-19 outbreak. J Neurol. https://doi.org/10.1007/s00415-020-10063-7

38. Jacob S, Muppidi S, Guidon A, Guttill J, Hehir M, Howard JD et al (2020) Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. https://doi.org/10.1016/j.jns.2020.116803

39. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419–425

40. Gable KL, Guttill JT (2020) Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis. Front Immunol. https://doi.org/10.3389/fimmu.2019.03052

41. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y et al (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 71(15):762–768. https://doi.org/10.1093/cid/ciaa248

42. Aruru M, Truong H-A, Clark S (2020) Pharmacy emergency preparedness and response (PEPR): a proposed framework for expanding pharmacy professionals’ roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond. Res Soc Adm Pharm. https://doi.org/10.1016/j.sapharm.2020.04.002

43. Société Française d’Anesthésie et de Réanimation. Comité éthique: à propos des décisions médicales d’admission des patients en unité de soins critiques en context pandémique : quelles remarques éthiques. Société Française d’Anesthésie et de Réanimation. https://srf.org/download/comite-ethique-a-propos-des-decisions-medicales-dadmission-des-patients-en-unite-de-soins-critiques-en-context-pandemique-quelques-remares-ethiques/. Accessed 27 May 2020

44. Vergano M, Bertolini G, Giannini A, Gris tina G, Livigni S, Mistraletti G, et al. (2020) Clinical ethics recommendations for the allocation of intensive care treatments, in exceptional, resource-limited circumstances. Recent Prog Med 111(4):207–211. https://doi.org/10.1701/3347.33183

45. Solé G, Salort-Campana E, Pereon Y, Stojkovic T, Wahbi K, Cintas P et al (2020) Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neurol (Paris). https://doi.org/10.1016/j.neurol.2020.04.004

46. Anand P, Slama MCC, Kaku M, Ong C, Cervantes-Arslanian AM, Zhou L, et al. (2020) COVID-19 in patients with myasthenia gravis. Muscle Nerve 62(2):254–258. https://doi.org/10.1002/mus.29618

47. Delfy S, Syed MI, Lisak RP, Zutshi D (2020) Myasthenic crisis in COVID-19. J Neurol Sci 414:116888

48. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A et al (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. https://doi.org/10.1001/jama.2020.5394

49. Arentz M, Yim E, Kllafi L, Lokhandwala S, Riedo FX, Chong M et al (2020) Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. https://doi.org/10.1001/jama.2020.4326

50. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061–1069

51. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H et al (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. https://doi.org/10.1016/s2213-2600(20)30079-5

52. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506

53. Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A et al (2014) Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 160:389–397

54. Hui DS, Chow BK, Lo T, Tsang OTY, Ko FW, Ng SS, et al. (2019) Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J 53(4):1802339. https://doi.org/10.1183/13993003.02339-2018

55. Hui DS, Chow BK, Lo T, Ng SS, Ko FW, Gin T et al (2015) Exhaled air dispersion during noninvasive ventilation via helmets and a total facemask. Chest 147:1336–1343

56. Racca F, Mongini T, Wolf A, Vianello A, Cutrera R, Sorbo LD et al (2013) Recommendations for anesthesia and perioperative management of patients with neuromuscular disorders. Minerva Anestesiol 79:15

57. Anesthesia and perioperative medical management of children with spinal muscular atrophy—GRAHAM—2009—Pediatric
Anesthesia—Wiley Online Library. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1460-9592.2009.03055.x. Accessed 28 Apr 2020

58. Petroni F, Accorsi A, Adriano E, Agrò F, Amicucci G, Antonelli M et al (2005) Recommendations for airway control and difficult airway management. Minerva Anestesiol 71:617–657

59. Klingler W, Lehmann-Horn F, Jurkat-Rott K (2005) Complications of anaesthesia in neuromuscular disorders. Neuromuscul Disord 15:195–206

60. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. (2020) Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis 34:101663. https://doi.org/10.1016/j.tmaid.2020.101663

61. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 105949 doi.org/10.1016/j.ijantimics.2020.101663

62. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M et al (2020) Eff of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 3:e208857–e208857

63. Silva JA, Silva MB, Skare TL (2007) Chloroquine and QTc interval. Clin Exp Rheumatol 25:795

64. Wasay M, Wolfe GI, Herrold JM, Burns DK, Barohn RJ (1998) Chloroquine myopathy and neuropathy with elevated CSF protein. Neurology 51:1226–1227

65. Varan O, Kucuk H, Tufan A (2015) Myasthenia gravis due to hydroxychloroquine. Reumatismo 67:849

66. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. (2020) Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med 382(24):2327–2336. https://doi.org/10.1056/NEJMa2007916

67. Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O, Proschan M, Mukadi D et al (2019) A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med 381:2293–2303

68. Diomaro F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al (2020) Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 24:4040–4047

69. Miller DK, Lenard J (1981) Antihistaminics, local anesthetics, and other amines as antiviral agents. PNAS 78:3605–3609

70. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, et al. (2020) Guidance on minimizing risk of drug-induced ventilricular arrhythmia during treatment of COVID-19: a statement from the canadian heart rhythm society. Can J Cardiol 36(6):948–951. https://doi.org/10.1016/j.cjca.2020.04.003

71. Park KM, Shin KJ, Kim SE, Park J, Ha SY, Kim BJ (2013) Prophylaxis of new-onset myasthenia gravis in a child with chronic inflammatory demyelinating polyradiculoneuropathy. J Clin Neurol 9(7):814–818. https://doi.org/10.1002/jmv.25801

72. Michot J-M, Albiges L, Chaput N, Saada V, Pomermet F, Griscelli F, et al. (2020) Tocilizumab, an anti-IL6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol

73. Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976–986

74. Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa et al (2019) Long-term safety and effi of eculizumab in generalised myasthenia gravis. Muscle Nerve 60:693–699

75. Molina JM, Delaugerre C, Le Goif J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. (2020) No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 50(4):384. https://doi.org/10.1016/j.medma.2020.03.006

76. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med

77. Rendsivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial—The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext#seccestitle150. Accessed 6 May 2020

78. Haydar D, Cory TJ, Bircket SE, Murphy BS, Pennypacker KR, Sinai AP et al (2019) Azithromycin polarizes macrophages to an M2 phenotype via inhibition of the STAT1 and NF-κB signaling pathways. J Immunol 203:1021–1030

79. Kawamura K, Ichikado K, Takaki M, Eguchi Y, Anan K, Suga M (2018) Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center. Int J Antimicrob Agents 51:918–924

80. Mcgonagle D, Sharif K, O’Regan A, Bridgewood C (2020) The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 19(6):102537. https://doi.org/10.1016/j.autrev.2020.102537

81. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J (2020) Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 92(7):814–818. https://doi.org/10.1002/jmv.25801

82. Michot J-M, Albiges L, Chaput N, Saada V, Pomermet F, Griscelli F, et al. (2020) Tocilizumab, an anti-IL6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol

83. Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976–986

84. Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa et al (2019) Long-term safety and effi of eculizumab in generalised myasthenia gravis. Muscle Nerve 60:693–699

85. Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, et al. (2020) Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: a statement from the canadian heart rhythm society. Can J Cardiol 36(6):948–951. https://doi.org/10.1016/j.cjca.2020.04.003

86. Park KM, Shin KJ, Kim SE, Park J, Ha SY, Kim BJ (2013) Prolonged corrected QT interval in patients with myotonic dystrophy type 1. J Clin Neurol 9:186–191

87. Purohit VP (1988) Chloroquine neuromyotoxicity. Am J Med 84(3 Pt 1):568

88. Mah Ming JB, Gill MJ (2003) Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS 17:207–210

89. de Kanter CTMM, Keuter M, van der Lee MJ, Koopmans PP

90. Gummi RR, Kukulka NA, Deroche CB, Govindarajan R (2019) Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve 60:693–699